Masahiro Okada MD, Presenter: Nothing to Disclose

Itaru Chiba, Abstract Co-Author: Nothing to Disclose

Gyou IIda, Abstract Co-Author: Nothing to Disclose

Yukiko? Nishikuramori, Abstract Co-Author: Nothing to Disclose

Yuko Iraha, Abstract Co-Author: Nothing to Disclose

Sadayuki Murayama MD, PhD, Abstract Co-Author: Nothing to Disclose

KIMEI AZAMA, Abstract Co-Author: Nothing to Disclose

1. To define the utility of urological malignancies on advanced PET/CT scanner. 2. To introduce a new quantitative parameter of peak standardized uptake value (SUVpeak) in addition to conventional parameters of SUVmax and SUVmean. 3. To know the advantage of PET/CT in the evaluation after treatment. 4. To recognize pitfalls of urological malignancies on PET/CT.  

1. Advanced PET/CT imaging  a) spatial resolution  b) quantification to molecular imaging  c) characterize and monitor the tiniest cancer lesions 2. Utility at pre-treatment 　a) Staging of urological malignancies (prostate, urinary bladder, kidney and testis) 　b) TNM classification 3. Utility at post-treatment 　a) To detect recurrence and metastasis after surgery 　b) To evaluate residual viability of cancer after radiotherapy 　c) To evaluate residual viability of cancer after chemotherapy 4. Pitfalls of PET/CT to diagnose urological malignancies  

http://abstract.rsna.org/uploads/2014/14004362/14004362_evvx.pdf

Okada, M, Chiba, I, IIda, G, Nishikuramori, Y, Iraha, Y, Murayama, S, AZAMA, K, Role of FDG-PET/CT in Urological Oncology: Staging and Post-treatment Evaluation.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004362.html